NCT06233903 2025-01-21
18F-mFBG Expression in Neural Crest Tumors and Organs Innervated by the Sympathetic Nervous System
Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)
Phase 2 Withdrawn
Clinical Trials
10 trialsNCT06182410 2024-08-07
Defibrotide Prophylaxis of Transplant Associated-Thrombotic Microangiopathy for Neuroblastoma
University of California, San Francisco
Phase 2 Withdrawn
NCT04909515 2022-09-01
Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GMCSF) and Isotretinoin for Consolidation of Patients With High-Risk Neuroblastoma in First Remission.
Y-mAbs Therapeutics
Phase 2 Withdrawn
NCT02011126 2018-08-07
Imetelstat Sodium in Treating Younger Patients With Relapsed or Refractory Solid Tumors
Children's Oncology Group
Phase 2 Withdrawn
NCT03013387 2017-08-25
Dosimetry Guided PRRT With 90Y-DOTATOC
University of Iowa
Phase 2 Withdrawn
NCT01048086 2016-06-21
90Y DOTA/Retinoic Acid for Neuroblastoma and Neuroendocrine Tumor (NET)
University of Iowa
Phase 2 Withdrawn
NCT00003273 2015-12-03
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor
NYU Langone Health
Phase 2 Withdrawn
NCT00992173 2015-11-26
Efficacy and Safety of Ultratraceā¢ Iobenguane I 131 in Neuroblastoma
Molecular Insight Pharmaceuticals, Inc.
Phase 2 Withdrawn
NCT00874315 2015-10-16
Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed or Refractory High-Risk NBL.
Nationwide Children's Hospital
Phase 2 Withdrawn
NCT00389766 2013-07-10
High-Dose Iodine I 131 Metaiodobenzylguanidine, Topotecan, and Peripheral Stem Cell Transplant in Treating Young Patients With Relapsed Stage 4 Neuroblastoma or Primary Resistant High-Risk Neuroblastoma
National Cancer Institute (NCI)
Phase 2 Withdrawn